Cancer Therapy : Clinical Phase I and Clinical Pharmacology Study of Bevacizumab , Sorafenib , and Low-DoseCyclophosphamide inChildren and Young Adults with Refractory / Recurrent Solid Tumors


Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and pharmacodynamics of sorafenib, bevacizumab, and low-dose oral cyclophosphamide in children and young adults with recurrent/refractory solid tumors. ExperimentalDesign: Sorafenib dosewas escalated from90 to110mg/m twice dailywithfixed doses of… (More)

5 Figures and Tables


  • Presentations referencing similar topics